US EditionPublished • loading... • Updated
MetaVia doses first patient in study of DA-1726 in obesity - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MetaVia doses first patient in study of DA-1726 in obesity - BioTuesdays
MetaVia (NASDAQ: MTVA) has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. According to MetaVia, Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability. In a statement, Hyung …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
